Toxic Shock Syndrome
Clinical Snapshot
Toxic shock syndrome (TSS) is a rapidly progressive, toxin-mediated multisystem illness driven by exotoxin-producing Staphylococcus aureus or Streptococcus pyogenes (group A streptococcus, GAS) — two genuinely distinct syndromes, staphylococcal TSS and streptococcal TSS (STSS), that share a common underlying mechanism (a bacterial superantigen bypassing normal antigen processing to trigger massive, nonspecific T-cell activation and a cytokine storm) but differ meaningfully in typical clinical context, case-fatality rate, and treatment nuance.[1][2] Both are true medical emergencies: shock and multi-organ failure can develop within hours of the first symptoms, and streptococcal TSS carries a case-fatality rate as high as 30-70%, dramatically higher than the under-3% mortality typical of staphylococcal TSS.[3][4]
This chapter is organized around a single, non-negotiable safety message: source control is not optional and not something to defer until after antibiotics are running. Any retained tampon, nasal packing, or wound packing must be physically removed immediately, and any suspected deep soft-tissue or wound focus needs urgent surgical evaluation — in genuine parallel with, not after, aggressive resuscitation and the first dose of antibiotics.
The historically well-known association with menstruation and superabsorbent tampon use is real but has become a less dominant presentation since tampon absorbency and composition changed in the 1980s-90s; non-menstrual TSS — from surgical wounds, burns, skin and soft-tissue infections, nasal packing after nasal surgery, and postpartum infection — is now at least as important and should never be under-considered simply because a patient is not menstruating.[5] This chapter covers both syndromes' presentation and diagnostic criteria, the essential and time-critical role of source control, empiric antibiotic therapy combining an antibacterial agent with clindamycin specifically for its toxin-production-suppressing mechanism, intravenous immunoglobulin (IVIG) as an adjunct in severe or refractory disease, and the aggressive supportive, ICU-level care this true emergency demands.
Recognize the Condition
Pathophysiology — why this is a toxin-mediated emergency, not a typical infection
The defining feature of TSS is the superantigen: a bacterial exotoxin (toxic shock syndrome toxin-1 [TSST-1] in most staphylococcal TSS; streptococcal pyrogenic exotoxins A, B, and C, among others, in streptococcal TSS) that bypasses the normal, highly selective process of antigen presentation. Rather than being processed and presented within the groove of an MHC class II molecule to a small number of antigen-specific T cells, a superantigen binds directly to the outside of MHC class II and to the T-cell receptor's variable beta chain — activating up to 20-30% of the entire T-cell population, compared with well under 0.01% for a conventional antigen.[4] The result is a massive, nonspecific cytokine storm (interleukin-1, interleukin-2, tumor necrosis factor-alpha, interferon-gamma) that drives capillary leak, vasodilation, hypotension, and rapid multi-organ dysfunction — a process that can unfold over hours, and one where clinically significant, culturable bacteremia is often absent in staphylococcal TSS even though the toxin's effects are severe.[4]
Two genuinely distinct syndromes — why the distinction matters at the bedside
Staphylococcal TSS
Classically associated with menstruation and tampon use — a 1980s epidemic (US incidence peaking around 13.7 per 100,000) tied to a specific generation of highly absorbent tampons, whose composition and absorbency standards changed substantially afterward.[5] Menstrual TSS still occurs and, in some recent surveillance data, remains identified more often in absolute terms than non-menstrual staphylococcal TSS — but the non-menstrual share of cases has risen steadily since the 1980s peak, and any retained foreign material (nasal packing, wound packing, a barrier contraceptive left in place) or any S. aureus-colonized wound, burn, or surgical site can trigger it.[5] Frank bacteremia is often absent; blood cultures are frequently negative even in confirmed cases, because the disease is driven by toxin already released at a localized site rather than by bloodstream invasion.[4]
Streptococcal TSS (STSS)
Usually — though not always — associated with an identifiable Streptococcus pyogenes soft-tissue focus: cellulitis, myositis, or, most seriously, necrotizing fasciitis, as well as surgical or postpartum wound infection. A nonspecific, flu-like prodrome (fever, chills, myalgia, nausea/vomiting) commonly precedes shock by 24-48 hours.[3] Bacteremia is common and blood cultures are frequently positive, unlike in staphylococcal TSS. In children, varicella (chickenpox) is a recognized portal of entry for secondary invasive GAS infection, and nonsteroidal anti-inflammatory drug (NSAID) use around a soft-tissue injury or varicella lesion has a real, if not fully settled, association with more severe disease (see Common Errors to Avoid).[6] Case-fatality is dramatically higher than staphylococcal TSS.[3]
Clinical presentation
Both syndromes classically present with abrupt-onset high fever (≥38.9°C/102°F), a diffuse, blanching macular erythroderma often described as looking like a sunburn — most prominent on the trunk and proximal extremities, and frequently accompanied by conjunctival and oropharyngeal mucosal hyperemia (and, in some staphylococcal cases, a "strawberry tongue") — together with rapidly progressive hypotension and evidence of multi-organ involvement: profuse vomiting and/or diarrhea early in the illness, severe myalgia, disorientation or altered mental status without a focal neurologic cause, and laboratory evidence of renal, hepatic, or hematologic dysfunction.[1][2] Desquamation — classically sheet-like peeling of the palms and soles — is a real and specific finding, but it is a late one, typically appearing 1-2 weeks after illness onset; it is useful for retrospectively confirming the diagnosis but must never be waited for before starting treatment.[1]
Risk Factors
- Menstruation with tampon use, particularly prolonged wear or a higher-absorbency product — a real but now less dominant risk factor than in the 1980s, given changes to tampon composition and absorbency standards since then.[5]
- Any other vaginal barrier device left in place: a menstrual cup, diaphragm, cervical cap, or contraceptive sponge.
- Nasal packing after nasal or sinus surgery, or for epistaxis control.[4]
- Any surgical wound, especially one with a retained foreign body, hematoma, or seroma; postpartum or post-abortion infection.
- Burns, and any skin or soft-tissue infection or abscess with S. aureus or S. pyogenes — the single most common source/risk factor for TSS overall.[4]
- Recent influenza — staphylococcal TSS is a recognized, serious complication of secondary staphylococcal infection following influenza.
- Varicella (chickenpox) in children — a recognized portal of entry for invasive, toxin-producing GAS.
- Nonsteroidal anti-inflammatory drug (NSAID) use around a soft-tissue injury, surgical site, or varicella lesion — an association with more severe group A streptococcal disease that is biologically plausible and supported by experimental and some clinical data, though not universally confirmed prospectively (see Common Errors to Avoid).[6]
- A prior episode of menstrual TSS without laboratory-confirmed seroconversion (development of protective antibody to the causative toxin) — associated with a real, clinically meaningful risk of recurrence with continued tampon use.[7]
- Diabetes, immunosuppression, and other chronic illness — general susceptibility factors for more severe invasive staphylococcal or streptococcal disease.
- Young age (for staphylococcal TSS specifically) — older adults are more likely to have already seroconverted to protective anti-TSST-1 antibody from prior subclinical colonization/exposure.
Red Flags & Refer
Unexplained high fever with a diffuse erythematous rash and hypotension is a medical emergency until proven otherwise — begin resuscitation, actively search for and remove any retained foreign material, and arrange urgent surgical evaluation of any possible soft-tissue source in parallel, not sequentially. Do not wait for desquamation, a positive culture, or a complete case-definition checklist to begin treatment when clinical suspicion is genuinely high.[1][2]
- Fever, diffuse macular erythroderma, and hypotension or shock in any patient, menstruating or not.
- Any menstruating patient using a tampon (or menstrual cup, diaphragm, or similar device) with an unexplained febrile illness — ask directly and remove the device immediately, even before the rest of the workup is complete.
- Any patient with nasal packing, wound packing, or other retained material with unexplained fever, rash, or hemodynamic instability.
- Pain that is disproportionate to visible skin findings, rapidly spreading erythema, bullae, skin necrosis, or crepitus over a wound or soft-tissue area — classic red flags for necrotizing fasciitis, which requires emergent surgical exploration and is a recognized precursor to streptococcal TSS.[8]
- A postpartum or post-surgical patient with unexplained fever and hypotension — examine the wound/uterus directly rather than attributing the picture to a more common postoperative or postpartum complication.
- A child with varicella and new high fever, severe localized pain, or rapid clinical deterioration.
- Any sign of multi-organ dysfunction (altered mental status, oliguria, coagulopathy, respiratory distress) accompanying a compatible febrile rash illness.
Assessment & Diagnosis
History and examination
Ask specifically about menstrual status and tampon/menstrual cup/diaphragm use (and confirm removal), recent surgery, wounds, burns, nasal packing, postpartum status, and varicella exposure — none of these should be assumed absent simply because the patient does not volunteer them. Perform a complete skin and mucosal examination, including the palms, soles, and conjunctivae/oropharynx, and inspect every wound, surgical site, and area of nasal packing directly rather than relying on the chart. In a patient with any possible soft-tissue focus, actively assess for the red flags of necrotizing infection: pain out of proportion to examination findings, rapidly advancing erythema, bullae, skin discoloration/necrosis, and crepitus.
Laboratory testing
Obtain a complete blood count (leukocytosis with a marked left shift/bandemia is typical), comprehensive metabolic panel (renal and hepatic function), creatine kinase (muscle involvement/myositis), coagulation studies including fibrinogen (disseminated intravascular coagulation is a recognized complication, especially in STSS), lactate, and two sets of blood cultures before the first antibiotic dose whenever feasible without materially delaying treatment — positive far more often in streptococcal TSS than in staphylococcal TSS, where a negative blood culture does not argue against the diagnosis.[4] Culture any wound, site of packing, or vaginal/cervical swab as applicable. Hypocalcemia can be prominent and clinically significant, and should be actively corrected.
Imaging
Imaging should never delay urgent surgical consultation or source control when clinical suspicion for a necrotizing or deep soft-tissue process is high. CT or MRI can help delineate the extent of soft-tissue involvement or identify an occult deep collection once the patient is stable enough, but a clinical picture strongly suggestive of necrotizing fasciitis warrants emergent surgical exploration regardless of imaging availability or findings.[8]
Diagnostic criteria
Both syndromes have formal CDC surveillance case definitions that combine clinical and laboratory criteria; they are genuinely useful for organizing the bedside assessment even though, in practice, treatment should never wait for a case to be formally classified.
| Staphylococcal TSS — clinical criteria (2011 CDC case definition) | Detail |
|---|---|
| Fever | Temperature ≥38.9°C (≥102.0°F) |
| Rash | Diffuse macular erythroderma |
| Desquamation | 1-2 weeks after rash onset (not required for a confirmed case if the patient dies before it occurs) |
| Hypotension | Systolic BP ≤90 mmHg (adults) or below the 5th percentile for age (children under 16) |
| Multisystem involvement (≥3 of 7 required) | Gastrointestinal (vomiting/diarrhea at onset); muscular (severe myalgia or CK ≥2× upper limit of normal); mucous membrane (vaginal, oropharyngeal, or conjunctival hyperemia); renal (BUN/creatinine ≥2× upper limit of normal, or pyuria without UTI); hepatic (bilirubin/ALT/AST ≥2× upper limit of normal); hematologic (platelets <100,000/mm³); CNS (disorientation/altered consciousness without focal signs, in the absence of fever/hypotension) |
| Laboratory criteria | Negative blood/CSF cultures other than possibly S. aureus, and negative serologies for Rocky Mountain spotted fever, leptospirosis, and measles |
| Case classification | Probable: laboratory criteria plus 4 of 5 clinical criteria. Confirmed: laboratory criteria plus all 5 clinical criteria (desquamation excepted if the patient dies first) |
| Streptococcal TSS (STSS) — clinical criteria (2010 CDC case definition) | Detail |
|---|---|
| Hypotension | Systolic BP ≤90 mmHg (adults) or below the 5th percentile for age (children under 16) |
| Multi-organ involvement (≥2 of 6 required) | Renal (creatinine ≥2 mg/dL [≥177 µmol/L], or ≥2× baseline in preexisting renal disease); coagulopathy (platelets ≤100,000/mm³, or DIC); hepatic (ALT/AST/total bilirubin ≥2× upper limit of normal); respiratory (ARDS); dermatologic (generalized erythematous macular rash, which may desquamate); soft-tissue (necrotizing fasciitis, myositis, or gangrene) |
| Laboratory criteria | Isolation of group A Streptococcus |
| Case classification | Probable: clinical criteria met plus GAS isolated from a non-sterile site, with no other identified cause. Confirmed: clinical criteria met plus GAS isolated from a normally sterile site (blood, CSF, joint, pleural, or pericardial fluid) |
[2] A simplified, clinically oriented version of the STSS definition — hypotension plus at least two of renal impairment, coagulopathy, liver dysfunction, ARDS, or a generalized erythematous rash — is used in current Canadian Paediatric Society guidance and is consistent with the CDC definition above.[3]
Treatment Targets
- Reverse shock and prevent progressive multi-organ failure with immediate, aggressive resuscitation.
- Achieve source control without delay: physically remove any retained tampon, menstrual cup, diaphragm, nasal packing, or wound packing, and obtain urgent surgical debridement of any infected or necrotic soft-tissue focus — this is genuinely time-critical and is not interchangeable with antibiotics.
- Start empiric combination antibiotic therapy immediately, pairing an antibacterial agent with clindamycin specifically to suppress ongoing toxin production.
- Consider IVIG early in severe or refractory disease, particularly streptococcal TSS with persistent shock, to help neutralize circulating superantigen.
- Provide ICU-level monitoring and organ support, anticipating rapid deterioration even after initial stabilization appears to begin.
- De-escalate to targeted therapy once an organism and susceptibilities are known, and confirm an appropriate total treatment duration.
- Arrange chemoprophylaxis for close contacts of a confirmed severe/invasive streptococcal case, and complete public health reporting.
- Counsel survivors of menstrual TSS on the real risk of recurrence with continued tampon use.
Choose Initial Treatment
Remove the source, resuscitate, and start a clindamycin-containing antibiotic combination — simultaneously, not sequentially
Every confirmed or strongly suspected case begin aggressive isotonic crystalloid resuscitation immediately, add norepinephrine as the first-line vasopressor for shock refractory to adequate fluid resuscitation (escalating to vasopressin or epinephrine if needed), and — in true parallel with antibiotics, not after — physically remove any retained tampon, menstrual cup, diaphragm, or nasal/wound packing and obtain urgent surgical consultation for debridement of any infected or necrotic soft-tissue focus.[4] Obtain blood and site cultures before the first antibiotic dose whenever feasible without meaningfully delaying treatment. Staphylococcal TSS, MRSA possible or organism not yet known Combo: vancomycin 15-20 mg/kg IV every 8-12 hours + clindamycin 900 mg IV every 8 hours — vancomycin for empiric MRSA/gram-positive coverage, plus clindamycin added specifically to suppress toxin production (see below). Staphylococcal TSS, confirmed MSSA Combo: cloxacillin 2 g IV every 4-6 hours + clindamycin 900 mg IV every 8 hours — a beta-lactamase-stable beta-lactam plus clindamycin. Streptococcal TSS (STSS), confirmed or strongly suspected Combo: penicillin G 2-4 million units IV every 4-6 hours + clindamycin 900 mg IV every 8 hours — penicillin G remains the treatment of choice once GAS is confirmed, but clindamycin is added in every case, not reserved for treatment failures, because of its distinct toxin-suppressing effect.[3] If the organism or source is unclear, or a polymicrobial necrotizing infection is possible, broaden empirically (e.g., vancomycin (IV) or piperacillin-tazobactam) pending cultures, while continuing clindamycin throughout.[8]
Why clindamycin is added to every regimen — a genuinely important, non-obvious pharmacologic point
Clindamycin's role in TSS is not simply another antibacterial option — it is added specifically for a distinct, additive mechanism. As a ribosomal (50S subunit) protein-synthesis inhibitor, clindamycin directly suppresses bacterial exotoxin production (TSST-1 in staphylococcal disease; streptococcal pyrogenic exotoxins and streptolysin O in streptococcal disease) — a laboratory finding first demonstrated for TSST-1 in 1984 and since shown for multiple staphylococcal and streptococcal toxins.[9] This effect is genuinely independent of, and additive to, clindamycin's modest antibacterial activity: a classic experimental model of streptococcal myositis found that delayed clindamycin dramatically outperformed delayed penicillin (survival of 70-100% versus no better than untreated controls once treatment was delayed even a few hours), an effect attributed in part to the so-called Eagle effect — beta-lactams require actively dividing bacteria with intact penicillin-binding proteins to work, and lose potency against the large, stationary-phase bacterial populations typical of an established toxin-producing infection, while clindamycin's protein-synthesis-inhibiting and toxin-suppressing mechanism does not depend on this.[10] In practice, this means clindamycin should be started alongside the primary antibacterial agent from the very first dose in every confirmed or strongly suspected case of either syndrome, not reserved as a second-line addition if the patient fails to improve.
Intravenous immunoglobulin (IVIG)
IVIG is an adjunct, not a substitute for antibiotics or source control, and works by neutralizing circulating superantigen before it can continue driving T-cell activation and cytokine release. The evidence base is genuinely stronger for streptococcal TSS: a systematic review and meta-analysis of clindamycin-treated STSS patients found IVIG was associated with a mortality reduction from 33.7% to 15.7% (risk ratio 0.46, 95% CI 0.26-0.83) — a number needed to treat of roughly 6 to prevent one additional death.[11] Current Canadian Paediatric Society guidance recommends considering IVIG on the day of clinical presentation for streptococcal TSS, using either immunoglobulin (human) 1-2 g/kg as a single dose, or 150-500 mg/kg/day for 5-6 days.[3] For staphylococcal TSS, the supporting evidence is considerably weaker and more mixed — staphylococcal disease may respond less reliably to IVIG than streptococcal disease — but it is still reasonably considered, often at a similar or higher single-dose regimen, for a patient with persistent shock or organ dysfunction despite adequate source control and antibiotics.[4]
Non-Pharmacologic Treatment
- Immediate removal of any retained tampon, menstrual cup, diaphragm, cervical cap, or contraceptive sponge — a simple, time-critical step that is easy to miss if the patient's menstrual/device history isn't asked about directly.
- Immediate removal of nasal or wound packing in any patient in whom it is present, regardless of how recently it was placed or how "routine" the original procedure was.
- Urgent surgical consultation and debridement of any confirmed or strongly suspected necrotizing soft-tissue infection, myositis, or infected surgical/postpartum wound — repeated as needed, since a single debridement is not always sufficient, and this is co-equal source control alongside antibiotics, not an adjunct to them.[8]
- Aggressive isotonic crystalloid fluid resuscitation, titrated to hemodynamic response, urine output, and lactate clearance, recognizing that capillary leak from the underlying cytokine storm can create very large ongoing fluid requirements.
- ICU admission with invasive hemodynamic monitoring for any patient with hypotension or organ dysfunction, given the genuine risk of rapid deterioration even after apparent initial stabilization.
- Respiratory support, up to and including mechanical ventilation, for ARDS or airway compromise from altered mental status.
- Renal replacement therapy if acute kidney injury progresses despite adequate resuscitation.
- Correction of hypocalcemia and other electrolyte derangements, which can be clinically significant in severe disease.
- Avoid nonselective NSAIDs for analgesia or antipyresis once significant soft-tissue infection or streptococcal disease is suspected; use acetaminophen preferentially (see Common Errors to Avoid).
- Droplet/contact precautions for confirmed invasive GAS until 24 hours of effective antibiotic therapy has been completed, and public health reporting of confirmed invasive group A streptococcal disease and TSS, which are reportable conditions.
- Chemoprophylaxis coordination for close contacts of a confirmed severe/invasive streptococcal case (see Special Populations).
Special Populations
Pediatrics
Apply the same principles as in adults, with weight-based dosing throughout. Varicella is a recognized portal of entry for invasive, toxin-producing GAS in children, and a febrile, unwell child with chickenpox and new, severe, localized pain deserves the same urgent evaluation as any other compatible presentation.[6] Avoid nonselective NSAIDs (including ibuprofen) for fever or pain control in a child with varicella or a possible soft-tissue infection — use acetaminophen instead.[6] IVIG dosing in children follows the same regimens used in adults: immunoglobulin (human) 1-2 g/kg as a single dose, or 150-500 mg/kg/day for 5-6 days, considered on the day of presentation for streptococcal TSS.[3]
Close contacts of a confirmed severe/invasive streptococcal case — chemoprophylaxis
Household and other close contacts of a patient with confirmed streptococcal TSS or another severe/invasive GAS infection (e.g., necrotizing fasciitis) carry a real, if small, increased risk of subsequent invasive GAS disease themselves, and current Canadian Paediatric Society guidance recommends chemoprophylaxis be offered.[3] First-line cephalexin 25-50 mg/kg/day (maximum 1 g/day) for 10 days. Beta-lactam allergy clarithromycin or clindamycin. Start prophylaxis as soon as possible — ideally within 24 hours of identifying a close contact — though it can still reasonably be offered up to about 7 days after the last contact with the index case.[3]
Pregnancy and postpartum
Postpartum staphylococcal or streptococcal TSS is a genuine, time-critical obstetric emergency, most often arising from a uterine, wound, or perineal source — do not let obstetric considerations delay urgent source control (wound exploration, evaluation for retained products of conception) or the first dose of antibiotics. vancomycin (IV), cloxacillin, penicillin G, and clindamycin are all generally considered compatible with pregnancy and breastfeeding at standard doses; involve obstetrics and infectious diseases jointly for a critically unwell pregnant or postpartum patient, and do not withhold IVIG on the basis of pregnancy alone when it is otherwise indicated for refractory shock.
Menstrual TSS survivors — recurrence risk
A patient recovering from menstrual TSS faces a real, clinically meaningful risk of recurrence with continued tampon use — in one of the earliest and most detailed cohorts, roughly a quarter of patients had at least one recurrent episode during a subsequent menstrual period, and recurrence was less common among patients who had actually received an appropriate beta-lactamase-resistant antistaphylococcal antibiotic (reinforcing that antibiotics matter in this condition beyond simple source removal).[7] Counsel every survivor explicitly to avoid tampons, menstrual cups, diaphragms, and similar products going forward, and consider referral for antibody/seroconversion assessment where available, since a documented lack of seroconversion to the causative toxin is associated with a substantially higher recurrence risk.
Monitoring & Follow-Up
- Reassess hemodynamics, urine output, mental status, and the extent of any rash/skin findings at least every few hours during the first 24-48 hours of critical illness, alongside serial renal, hepatic, and coagulation studies.
- Expect meaningful clinical improvement within about 24-48 hours of adequate source control and antibiotics (plus IVIG where given) — a plateau or worsening picture should prompt reassessment rather than simply continuing the same plan (see Treatment Failure/Next Step).
- Reassess any debrided wound or surgical site regularly; repeat debridement is common and expected in necrotizing infection, not a sign that the original plan failed.
- Confirm total antibiotic duration is individualized to the source, organism, and clinical trajectory — commonly around 10-14 days for uncomplicated disease once source control is adequate, longer with bacteremia, endocarditis, retained deep infection, or necrotizing fasciitis requiring staged debridement.[4]
- Counsel patients and families that desquamation, typically beginning 1-2 weeks after illness onset and classically involving the palms and soles, is an expected part of recovery — not a sign of ongoing or worsening infection.[1]
- Confirm chemoprophylaxis has been offered and, where accepted, completed for close contacts of a confirmed severe/invasive streptococcal case, and that public health reporting has been completed.[3]
- Before discharge, explicitly counsel any survivor of menstrual TSS on tampon/device avoidance and the real recurrence risk with continued use.[7]
- Arrange follow-up for any organ dysfunction present at discharge (renal function, cardiac function, cognitive/neurologic status) and for reconstructive or wound-care needs after extensive debridement.
Common Errors to Avoid
- Waiting for desquamation to "confirm" the diagnosis before starting treatment — it is a real but late finding that appears 1-2 weeks after onset and must never delay care.[1]
- Not actively asking about, or forgetting to search for and remove, a retained tampon, menstrual cup, diaphragm, or nasal/wound packing — an easy-to-miss, genuinely time-critical step.
- Treating suspected staphylococcal or streptococcal TSS with a beta-lactam or vancomycin alone, without adding clindamycin from the first dose — this forfeits a real, mechanistically distinct toxin-suppression benefit.[9][10]
- Assuming TSS is exclusively a "menstrual disease" and not considering it in a non-menstruating patient, a man, a child, or a postmenopausal woman with a compatible wound, surgical, or burn source.
- Using nonselective NSAIDs (e.g., ibuprofen) for pain or fever control once a significant soft-tissue infection or streptococcal disease is suspected — prefer acetaminophen; the evidence for causing worse outcomes is genuinely mixed, but experimental data and biologic plausibility both support caution.[6]
- Delaying surgical consultation or debridement to obtain imaging or await culture results when the clinical picture is strongly suggestive of necrotizing soft-tissue infection.[8]
- Under-recognizing that streptococcal TSS carries a dramatically higher case-fatality rate than staphylococcal TSS, and under-triaging a patient with a compatible presentation and a possible streptococcal source as a result.[3]
- Failing to arrange chemoprophylaxis for close contacts after a confirmed severe/invasive streptococcal case.[3]
- Not offering explicit counseling on tampon/device avoidance after a menstrual TSS episode, given the real and meaningful recurrence risk with continued use.[7]
Clinical Decision Algorithm
Drug Tables
How to use this table: Doses are adult doses and require patient-specific confirmation (renal/hepatic function, weight, allergy history). Pediatric dosing is weight-based per the current product monograph unless stated. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.
Empiric and Targeted Antibacterial Therapy — Staphylococcal TSS
Obtain blood and site cultures before the first dose whenever feasible. Always given in combination with clindamycin (see below), never as monotherapy.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Vancomycin (IV) | Adults: 15-20 mg/kg IV every 8-12 hours, adjusted to levels/AUC and renal function | Nephrotoxicity, infusion-related reaction ("red man syndrome"), ototoxicity | Additive nephrotoxicity with other nephrotoxic drugs (e.g., aminoglycosides) | Empiric choice when MRSA is possible or the organism is unknown; requires trough/AUC monitoring and renal-function-based dosing. |
| Cloxacillin | Adults: 2 g IV every 4-6 hours | GI upset, hypersensitivity reactions | May reduce efficacy of estrogen-containing contraceptives (theoretical) | Preferred, narrower option once MSSA is confirmed. |
| Linezolid | Adults: 600 mg PO/IV every 12 hours | Thrombocytopenia/myelosuppression beyond ~2 weeks, serotonin syndrome risk, peripheral/optic neuropathy with prolonged use | Serotonin syndrome risk with SSRIs/SNRIs/MAOIs; weak MAOI activity | MRSA alternative with excellent oral bioavailability and some independent toxin-suppressing activity. |
| Daptomycin | Adults: 6 mg/kg IV once daily | CPK elevation/myopathy — monitor weekly | Increased CPK-elevation risk with a statin | MRSA alternative for vancomycin intolerance or treatment failure; does not suppress toxin production — pair with clindamycin or linezolid. |
Empiric and Targeted Antibacterial Therapy — Streptococcal TSS (STSS)
Always given in combination with clindamycin. Broaden empirically (e.g., vancomycin or piperacillin-tazobactam) if the source or organism is unclear, or a polymicrobial necrotizing infection is possible, pending cultures.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Penicillin G | Adults: 2-4 million units IV every 4-6 hours | Hypersensitivity, electrolyte disturbance (potassium load) with very high doses, seizures at very high doses in renal impairment | None significant at standard doses | Treatment of choice once GAS is confirmed; group A streptococcus remains uniformly penicillin-susceptible. |
| Piperacillin/Tazobactam | Adults: 3.375-4.5 g IV every 6-8 hours, extended infusion preferred for serious infection | GI upset, hypersensitivity, electrolyte disturbance | Reduced efficacy of some anticoagulant monitoring assays | Broad empiric option when a polymicrobial necrotizing infection is possible pending culture results. |
Toxin-Suppression Adjunct — Added to Every Regimen, Both Syndromes
Started from the first dose alongside the primary antibacterial agent — not reserved for treatment failure. See Choose Initial Treatment for the mechanistic rationale.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Clindamycin | Adults, severe/confirmed disease: 900 mg IV every 8 hours Adults, general range: 600-900 mg IV every 8 hours | Clostridioides difficile-associated diarrhea, GI upset | None significant at standard doses | Inhibits ribosomal protein synthesis, shutting off exotoxin production independent of, and additive to, its antibacterial activity. |
Antitoxin Adjunct — Severe or Refractory Disease
An adjunct to, never a substitute for, source control and antibiotics.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Immunoglobulin (Human) — IVIG | Single dose: 1-2 g/kg IV Divided regimen: 150-500 mg/kg/day IV for 5-6 days | Aseptic meningitis, hemolytic anemia, anaphylaxis in IgA-deficient patients, renal impairment with rapid infusion | May reduce the efficacy of live vaccines given within about 11 months of infusion | Strongest evidence in streptococcal TSS with persistent shock (mortality reduction from 33.7% to 15.7% in a meta-analysis of clindamycin-treated patients); weaker, more mixed evidence in staphylococcal TSS. |
Hemodynamic Support
For shock refractory to adequate isotonic crystalloid resuscitation.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Norepinephrine | Adults: Continuous IV infusion, titrated to mean arterial pressure target | Peripheral/digital ischemia with extravasation or high doses, arrhythmia | Additive hypertensive effect with other vasopressors/MAOIs | First-line vasopressor; give through central access when feasible. |
| Vasopressin | Adults: Fixed-dose continuous IV infusion (not titrated with blood pressure) | Peripheral/mesenteric ischemia, hyponatremia | Additive hypertensive effect with other vasopressors | Add-on, fixed-dose infusion to reduce catecholamine requirement in refractory shock. |
| Epinephrine | Adults: Continuous IV infusion, titrated to mean arterial pressure target | Tachyarrhythmia, hyperglycemia, lactate elevation | Additive hypertensive effect with other vasopressors/MAOIs | Alternative or additional vasopressor for shock refractory to norepinephrine and vasopressin. |
Analgesia and Antipyresis
Prefer acetaminophen over nonselective NSAIDs once significant soft-tissue infection or streptococcal disease is suspected (see Common Errors to Avoid).
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Acetaminophen | Adults: 650-1000 mg PO/IV every 4-6 hours as needed, maximum per product labelling | Hepatotoxicity in overdose or with chronic excessive use | Increased hepatotoxicity risk with chronic alcohol use | Preferred agent for fever and pain control in this setting. |
| Ibuprofen | Not recommended in this context: N/A | May mask evolving signs of worsening soft-tissue infection; GI upset/bleeding, renal impairment | Increased bleeding risk with anticoagulants/antiplatelets | Avoid once significant soft-tissue infection or streptococcal disease is suspected or confirmed — switch to acetaminophen. |
Close-Contact Chemoprophylaxis — Confirmed Severe/Invasive Streptococcal Disease
Start as soon as possible, ideally within 24 hours of identifying a close contact; can still reasonably be offered up to about 7 days after the last contact with the index case.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Cephalexin | Adults and children: 25-50 mg/kg/day divided, to a maximum of 1 g/day, for 10 days | GI upset, hypersensitivity reactions | None significant at standard doses | First-line chemoprophylaxis agent. |
| Clarithromycin | Adults and children: Per product labelling, twice-daily dosing for 10 days | GI upset, QTc prolongation | Potent CYP3A4 inhibitor — numerous significant interactions (e.g., statins, calcium channel blockers) | Alternative for a penicillin/cephalosporin-allergic close contact. |
| Clindamycin | Adults and children: Per product labelling, dosed for 10 days | Clostridioides difficile-associated diarrhea, GI upset | None significant at standard doses | Alternative chemoprophylaxis option for penicillin allergy, particularly where local resistance patterns support it. |
References
- Toxic Shock Syndrome (Other Than Streptococcal) (TSS) 2011 Case Definition — National Notifiable Diseases Surveillance System, Centers for Disease Control and Prevention. CDC NNDSS, 2011 case definition
- Streptococcal Toxic Shock Syndrome (STSS) (Streptococcus pyogenes) 2010 Case Definition — National Notifiable Diseases Surveillance System, Centers for Disease Control and Prevention. CDC NNDSS, 2010 case definition
- Invasive group A streptococcal disease: Management and chemoprophylaxis — Canadian Paediatric Society, Infectious Diseases and Immunization Committee (Moore DL, Allen UD, Mailman T). Posted April 15, 2019, reaffirmed November 21, 2024
- Toxic Shock Syndrome — StatPearls Publishing (Ross A, Shoff HW). StatPearls, last updated August 7, 2023
- Toxic Shock Syndrome: A Literature Review — Antibiotics (Basel) (Atchade E, De Tymowski C, Grall N, Tanaka S, Montravers P). Antibiotics (Basel) 2024;13(1):96
- The roles of injury and nonsteroidal anti-inflammatory drugs in the development and outcomes of severe group A streptococcal soft tissue infections — Current Opinion in Infectious Diseases (Bryant AE, Bayer CR, Aldape MJ, Stevens DL). Curr Opin Infect Dis 2015;28(3):231-239
- Toxic-shock syndrome: epidemiologic features, recurrence, risk factors, and prevention — New England Journal of Medicine (Davis JP, Chesney PJ, Wand PJ, LaVenture M). N Engl J Med 1980;303(25):1429-1435
- Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America — Clinical Infectious Diseases, Infectious Diseases Society of America (Stevens DL, Bisno AL, Chambers HF, et al.). Clin Infect Dis 2014;59(2):e10-e52
- Clindamycin-induced suppression of toxic-shock syndrome-associated exotoxin production — Journal of Infectious Diseases (Schlievert PM, Kelly JA). J Infect Dis 1984;149(3):471
- The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis — Journal of Infectious Diseases (Stevens DL, Gibbons AE, Bergstrom R, Winn V). J Infect Dis 1988;158(1):23-28
- Polyspecific Intravenous Immunoglobulin in Clindamycin-treated Patients With Streptococcal Toxic Shock Syndrome: A Systematic Review and Meta-analysis — Clinical Infectious Diseases (Parks T, Wilson C, Curtis N, Norrby-Teglund A, Sriskandan S). Clin Infect Dis 2018;67(9):1434-1436
Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.